OBJECTIVE: Type-specific prevalence data of human papillomavirus (HPV) DNA in penile carcinoma are needed to determine the potential impact of HPV prophylactic vaccines, assuming demonstrated efficacy in men. METHODS: A review was conducted using search terms including HPV and penile cancer. Studies using polymerase chain reaction (PCR) assays for HPV DNA detection in invasive penile carcinoma were included. RESULTS: A total of 1,266 squamous cell carcinoma (SCC) cases contributed data from 30 studies. The number of SCC was similar in Europe (28.2%), North America (27.6%), South America (23.9%) and Asia (20.4%). All SCC were histologically confirmed with biopsies for DNA detection. Most commonly used PCR primers were type-specific (35.2%), and combination PCR (18.2%). HPV prevalence was 47.9%, ranging from 22.4% in verrucous SCC to 66.3% for the basaloid/warty subtypes. HPV16 (30.8%), HPV6 (6.7%) and HPV18 (6.6%) were the most prevalent types. HPV16 and/or HPV 18 prevalence was 36.7%. CONCLUSIONS: HPV DNA was detected in half of SCC, with HPV16 being the most common type. If proven efficacious in men, prophylactic vaccines targeting carcinogenic types HPV16 and 18 could potentially reduce approximately one-third of incident SCC.
OBJECTIVE: Type-specific prevalence data of human papillomavirus (HPV) DNA in penile carcinoma are needed to determine the potential impact of HPV prophylactic vaccines, assuming demonstrated efficacy in men. METHODS: A review was conducted using search terms including HPV and penile cancer. Studies using polymerase chain reaction (PCR) assays for HPV DNA detection in invasive penile carcinoma were included. RESULTS: A total of 1,266 squamous cell carcinoma (SCC) cases contributed data from 30 studies. The number of SCC was similar in Europe (28.2%), North America (27.6%), South America (23.9%) and Asia (20.4%). All SCC were histologically confirmed with biopsies for DNA detection. Most commonly used PCR primers were type-specific (35.2%), and combination PCR (18.2%). HPV prevalence was 47.9%, ranging from 22.4% in verrucous SCC to 66.3% for the basaloid/warty subtypes. HPV16 (30.8%), HPV6 (6.7%) and HPV18 (6.6%) were the most prevalent types. HPV16 and/or HPV 18 prevalence was 36.7%. CONCLUSIONS:HPV DNA was detected in half of SCC, with HPV16 being the most common type. If proven efficacious in men, prophylactic vaccines targeting carcinogenic types HPV16 and 18 could potentially reduce approximately one-third of incident SCC.
Authors: Alan G Nyitray; Roberto J Carvalho da Silva; Maria Luiza Baggio; Beibei Lu; Dan'elle Smith; Martha Abrahamsen; Mary Papenfuss; Manuel Quiterio; Luisa L Villa; Anna R Giuliano Journal: Sex Transm Dis Date: 2011-10 Impact factor: 2.830
Authors: J Kranz; A Parnham; M Albersen; V Sahdev; M Ziada; R Nigam; A Muneer; J Steffens; P Malone Journal: Urologe A Date: 2017-10 Impact factor: 0.639
Authors: Sheila F Faraj; Nilda Gonzalez-Roibon; Enrico Munari; Rajni Sharma; Arthur L Burnett; Antonio L Cubilla; George J Netto; Alcides Chaux Journal: Virchows Arch Date: 2017-03-27 Impact factor: 4.064
Authors: Danielle M Backes; Maaike C G Bleeker; Chris J L M Meijer; Michael G Hudgens; Kawango Agot; Robert C Bailey; J O Ndinya-Achola; Juma Hayombe; Cornelis J A Hogewoning; Stephen Moses; Peter J F Snijders; Jennifer S Smith Journal: Int J Cancer Date: 2011-08-02 Impact factor: 7.396
Authors: Jennifer S Smith; Danielle M Backes; Michael G Hudgens; Robert C Bailey; Giovanni Veronesi; Martijn Bogaarts; Kawango Agot; J O Ndinya-Achola; Ian Maclean; Walter Agingu; Chris J L M Meijer; Stephen Moses; Peter J F Snijders Journal: Int J Cancer Date: 2010-01-15 Impact factor: 7.396